Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
52 citations
,
May 2011 in “Journal of Neuroendocrinology” PEA boosts allopregnanolone production and reduces oxidative stress in brain cells.
May 2023 in “Scientific Reports” The seed extract of Lepidium sativum L. can potentially treat hair loss, showing effects similar to 5% minoxidil.
61 citations
,
September 2011 in “Pain” PEA reduces pain by increasing neurosteroid synthesis in the spinal cord.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” May 2024 in “Reactions weekly”
17 citations
,
December 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists found new, better-working inhibitors for a hormone-related enzyme.
July 2024 in “Reactions Weekly” 36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
8 citations
,
February 2013 in “Neuroscience Letters” Allopregnanolone may help prevent nicotine withdrawal symptoms.
3 citations
,
March 2016 in “Phytotherapy Research” The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
1 citations
,
April 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors are effective treatments for alopecia areata.
5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
March 2026 in “Tropical Journal of Natural Product Research” Albizia saponaria bark extract may help treat hair loss.
The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.
December 2025 in “International Journal of Dermatology” Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
42 citations
,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
37 citations
,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
June 2025 in “Korean Journal of Pharmacognosy” Isoalantolactone promotes hair growth by activating specific cell pathways.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
October 2024 in “International Journal of Pharmaceutics” The finasteride patch effectively treats hair loss by enhancing skin absorption.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology”
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.